Click any tag below to further narrow down your results
Links
Copenhagen startup BioinvestGPT runs virtual versions of drug trials with its AI models, and it says its forecasts were right in five of six cases so far. The companies behind these tools hope that testing drugs in simulation first will help more of them succeed in real human studies.
- BioinvestGPT shared its predictions for several high-profile drug trials with Reuters in July, before those results were public.
- The firm has been correct in five of six of those forecasts so far, a small sample that still needs more track record to judge.
- The pitch is that better virtual trials could cut the failure rate of expensive human studies.
Andreessen Horowitz has successfully raised over $15 billion to invest in various sectors, including AI, crypto, and health, aiming to ensure America's technological leadership. The firm emphasizes the importance of providing opportunities for individuals to contribute to society while addressing the competitive landscape against China.
- a16z raised over $15B to invest across AI, crypto, and health/biotech
- The firm frames its mission around maintaining American technological leadership, particularly against China
- The pitch emphasizes giving individuals the resources and opportunity to build and contribute to society
Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.
- Boltz raised a $28 million seed round and partnered with Pfizer to advance open-source drug design models.
- Over 100,000 scientists are already using Boltz's tools, positioning it as a widely-adopted open-science alternative to closed AI drug discovery platforms.
- The core bet is that open-source, freely accessible AI models can accelerate biological research and drug development faster than proprietary approaches.